TUSTIN, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients. The trial’s planned total of 46 patients has been enrolled and patients are currently undergoing treatment and follow-up. The primary objective of the multi-center, open-label study is to assess the overall tumor response to the regimen of bavituximab in combination with carboplatin/paclitaxel. Separately, the company announced issuance of a new U.S. patent with claims covering the use of bavituximab in combination with a broad range of cancer therapeutic agents. Peregrine is currently conducting three separate Phase II studies testing bavituximab in combination with docetaxel or carboplatin and paclitaxel in advanced breast and lung cancer patients. These combination therapies, which have shown promising initial results, are all covered under the claims in the newly issued patent.
